ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) shares fell to a low of $21.02 before closing at $21.23. Intraday shares traded counted 1.66 million, which was 37.73% higher than its 30-day average trading volume of 2.67M. ACAD’s previous close was $21.77 while the outstanding shares total 160.01M. The firm has a beta of 0.73. The stock’s Relative Strength Index (RSI) is 44.30, with weekly volatility at 5.99% and ATR at 0.93. The ACAD stock’s 52-week price range has touched low of $19.20 and a $58.72 high. The stock traded lower over the last trading session, losing -2.48% on 05/17/21.
Investors have identified the Biotechnology company ACADIA Pharmaceuticals Inc. as an interesting stock but before investments are made there, an in-depth look at its trading activities will have to be conducted. The share is trading with a market value of around $3.31 billion, the company now has both obstacles and catalysts that affect them and they came from their mode of operations. With the company affected by events currently, it is a perfect time to analyze the numbers behind the firm in order to come up with a rather realistic picture of what this stock is.
ACADIA Pharmaceuticals Inc. (ACAD) Fundamentals that are to be considered.
When analyzing a stock, the first fundamental thing to take into account is the balance sheet. How healthy the balance sheet of a company is will determine if the company will be able to carry out all its financial and non-financial obligations and also keep the faith of its investors. In terms of their assets, the company currently has 673.98 million total, with 109.37 million as their total liabilities.
Having a look at the company’s valuation, the company is expected to record -0.83 total earnings per share during the next fiscal year. It is very important though to remember that the importance of trend far outweighs that of outlook. This analysis has been great and getting further updates on ACAD sounds very interesting.
Is the stock of ACAD attractive?
In related news, EVP and CFO, Ridloff Elena sold 1,032 shares of the company’s stock in a transaction that recorded on Apr 30. The sale was performed at an average price of 20.33, for a total value of 20,981. As the sale deal closes, the EVP & General Counsel, KIM AUSTIN D. now sold 1,054 shares of the company’s stock, valued at 21,428. Also, President, Stankovic Srdjan R. sold 4,230 shares of the company’s stock in a deal that was recorded on Apr 30. The shares were price at an average price of 20.33 per share, with a total market value of 85,996. Following this completion of acquisition, the CEO, DAVIS STEPHEN now holds 7,850 shares of the company’s stock, valued at 159,590. In the last 6 months, insiders have changed their ownership in shares of company stock by 0.10%.
8 out of 20 analysts covering the stock have rated it a Buy, while 12 have maintained a Hold recommendation on ACADIA Pharmaceuticals Inc.. 0 analysts has assigned a Sell rating on the ACAD stock. The 12-month mean consensus price target for the company’s shares has been set at $29.17.